XtenCHO™ High-Density Expression: 500–1,500 mg/L Antibody Yields in Transient Timelines | AtaGenix

The Problem with Standard Transient Systems

Transient expression in CHO cells is the fastest route from antibody sequence to purified protein — but conventional systems often hit a ceiling. Cell viability drops after day 5–7, limiting culture duration and final titer. Yields for "average" antibodies hover around 100–300 mg/L, and difficult molecules (bispecifics, heavily glycosylated variants, non-standard Fc backbones) may fall below 50 mg/L. For programs that need milligram-to-gram quantities for preclinical studies, this means either multiple transfection batches (inconsistent) or early commitment to stable cell line development (slow and expensive).

XtenCHO™ was engineered to close this gap: a genetically optimized CHO host with proprietary media formulation that sustains high cell density and viability for 15 days, pushing transient yields into the range typically associated with stable pools — without the 8–12 week timeline of cell line development.

Cell Growth & Viability Performance

In head-to-head comparisons across multiple CHO lines carrying different antibody constructs, XtenCHO™ demonstrated consistent growth kinetics and exceptional viability retention:

Figure 1. Cell density and viability across multiple CHO lines over 15 days. Most lines expanded steadily to high density while maintaining near-100% viability through day 12–13. Minor viability decline near day 15 in select lines is typical of extended culture and manageable through optimized feeding strategies.

Key observations:

• Cell density: Steady expansion across all lines, reflecting optimized growth conditions. Clone-to-clone differences reflect natural variability in expression construct burden and line-specific metabolism — not platform limitations.
• Viability: Near-100% through most of the culture period. The slight late-phase decline in select lines can be mitigated through feed timing adjustments and optimized harvest windows — standard process development that AtaGenix supports for every project.

Antibody Yield Across 11 Molecules

To demonstrate platform versatility, AtaGenix benchmarked XtenCHO™ across 11 different therapeutic antibody molecules spanning multiple IgG subclasses and engineered formats:

Figure 2. Antibody yields across 11 therapeutic molecules expressed in XtenCHO™. The majority of molecules achieved 500–1,000 mg/L, with the top performer reaching ~1,500 mg/L. A small number of outliers below 100 mg/L reflect sequence-specific challenges (e.g., secretion bottlenecks, glycan complexity) that can typically be addressed through leader peptide optimization or process adjustments.

What the yield data tells us:

• Median range (500–1,000 mg/L): Sufficient for most preclinical applications from a single transfection batch — no need for multiple production runs or early stable line commitment.
• Top titer (~1,500 mg/L): Approaching stable pool performance in a transient format, demonstrating the ceiling of the platform for well-behaved molecules.
• Low outliers (<100 mg/L): Present in every expression platform. AtaGenix addresses these through construct engineering (signal peptide screening, codon re-optimization) and process modifications (temperature shift, feed timing) — often recovering 3–5× improvement.

XtenCHO™ vs. Standard Transient Expression

Yield data based on internal benchmarking across 11 therapeutic antibody molecules. Results may vary depending on antibody sequence, format, and process conditions. XtenCHO™ is a proprietary platform of AtaGenix Laboratories.